Leadership Team2021-08-19T23:36:59+00:00
COMPANY

Leadership Team

COMPANY

Leadership
Team

Improving the quality of healthcare worldwide

Committed to providing high quality, reliable, cutting-edge tools for molecular diagnostic and personalized molecular medicine.

Improving the quality of healthcare worldwide

Committed to providing high quality, reliable, cutting-edge tools for molecular diagnostic and personalized molecular medicine.

JEFFREY EDWARD MILLER, PH.D.
JEFFREY EDWARD MILLER, PH.D.
FOUNDER, CHIEF SCIENTIFIC OFFICER, CHIEF EXECUTIVE OFFICER & CHAIRMAN

Dr. Miller is a scientist, inventor, entrepreneur focused on Improving Lives with Precision Diagnostics® – coupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.
Prior to starting Invivoscribe, Dr. Miller had more than twenty years of combined experience in protein biochemistry, cellular and molecular immunology, cardiac physiology, virology, and molecular biology, experience he had developed working in laboratories at the Medical School, Department of Chemistry, Molecular Biology Institute at UCLA, while earning his Ph.D. at UCSB, and as a postdoctoral scientist at Applied Molecular Evolution. He also spent several years at Quest Diagnostics Nichols Institute, setting up the molecular oncology laboratory and developing and launching PCR-based molecular assays for infectious disease and hematopathology.
Dr. Miller has a number of patents, peer-reviewed publications, and he has contributed to chapters in textbooks. He has been a member of the Association for Molecular Pathology for more than two decades, and is a member of ASH, EHA, and ASCO.
MEGHNA BHATNAGAR
MEGHNA BHATNAGAR
CHIEF FINANCIAL OFFICER

Meghna Bhatnagar joined Invivoscribe in 2010 as Chief Financial Officer. In this role she is responsible for leading the Invivoscribe global finance organization, along with human resources and information technology.
Meghna Bhatnagar joined Invivoscribe in 2010 as Chief Financial Officer. In this role she is responsible for leading the Invivoscribe global finance organization, along with human resources and information technology.
Since her arrival, Ms. Bhatnagar has played an integral role in directing all aspects of company strategy, planning and operations.
Ms. Bhatnagar has over 20 years of experience building and leading finance and IT teams in global companies. Prior to joining IVS, she served as COO of Radiant Technologies, a technology company focused on providing business management solutions to small and medium sized companies where she was responsible for leadership and development of an entire project delivery team with full P&L responsibility. She played a key role in guiding overall strategy of the company and at the same time provided leadership for operational improvements.
Ms. Bhatnagar began her career in at Nunhems Seeds, a company of Bayer AG. During her tenure at Bayer she managed comprehensive portfolio of responsibilities in Finance and Information Technology both at regional and global levels.
Ms. Bhatnagar graduated from Kurukshetra University in India with bachelor’s degree in Accounting and earned a MBA from MDI, a premier business school in India.
TONY LIALIN
TONY LIALIN
CHIEF COMMERCIAL OFFICER

Tony Lialin joined Invivoscribe in 2021 as Chief Commercial Officer. In this role he is responsible for leading the global commercial organization.
Mr. Lialin has more than two decades of experience in growing companies in the life sciences industry having held positions in clinical diagnostic, bioinformatics software, instrumentation and reagent companies.
He has successfully scaled commercial operations at three start-ups resulting in those companies being purchased by large public companies.
Mr. Lialin comes to IVS from Loop Genomics, an NGS long-read sequencing company where he started their global commercial operations growing their business to several million dollars in revenue per year in just three years.  From 2014 through June 2018, Mr. Lialin managed $400M in portfolio business at Illumina working closely with customers in the DTC, Oncology and Postnatal testing spaces.   He also served as a director at Agilent Technologies, where he managed the emerging market, field application scientist, and technical support and field service engineering teams.  As a six-sigma green belt he values process, service as a differentiator and both internal and external customers.
Mr. Lialin earned a BA in Molecular Cellular and Developmental Biology from the University of California at Santa Cruz.
DR. BRADLEY PATAY, M.D.
DR. BRADLEY PATAY, M.D.
CHIEF MEDICAL OFFICER

Dr. Patay is dedicated to improving health by integrating genomic knowledge into medical care. He has authored numerous articles in this field, presented at multiple conferences and has been featured in Bloomberg Business Week.
Dr. Patay is dedicated to improving health by integrating genomic knowledge into medical care. He has authored numerous articles in this field, presented at multiple conferences and has been featured in Bloomberg Business Week. He has been head of the internal medicine section at Scripps Torrey Pines, worked as an Assistant Professor at STSI, and has been a founding member of the Board, and Vice President of the College of Genomic Medicine, which was established in 2010 to educate physicians and other health care professionals about genomic medicine.
His diverse clinical experience prior to joining Scripps Clinic in 2005 includes four years as an internist and pediatrician at Neighborhood Healthcare, a private, nonprofit community healthcare practice, and at Palomar Hospital. At these institutions, Brad cared for a wide range of patients, from neonates to the elderly, in both intensive care and the general wards. Through his service on several committees, he helped improve the health care institutions’ systems.
Dr. Patay has also been both a principle investigator and sub-investigator on studies that have integrated genomic and phenotypic data into models that help elucidate such topics as blood pressure, longevity and cancer. He also serves on a committee that helps select patients for genome sequencing to elucidate their unknown conditions.
He graduated with honors in economics and molecular cell biology from the University of California at Berkeley and he was elected to Phi Beta Kappa. After receiving his M.D. degree at UC San Diego in 1997, he completed a medical residency at Banner Health in Phoenix, Arizona and earned board certifications in Internal Medicine and Pediatrics.
PAUL MCMULLIN
PAUL MCMULLIN
HEAD OF GLOBAL SALES & MARKETING

Paul McMullin joined Invivoscribe in 2018 as the Head of Global Sales & Marketing. In this role, he leads Invivoscribe’’s worldwide Sales and Marketing efforts with focus on both Diagnostic and Companion Diagnostics (CDx) Products. These Products are sold in over 100 Countries via a Direct Sales Organization as well as Exclusive Distributors.
Paul McMullin joined Invivoscribe in 2018 as the Head of Global Sales & Marketing. In this role, he leads Invivoscribe’’s worldwide Sales and Marketing efforts with focus on both Diagnostic and Companion Diagnostics (CDx) Products. These Products are sold in over 100 Countries via a Direct Sales Organization as well as Exclusive Distributors.
Mr. McMullin has over 35 years of experience working in the Medical Diagnostics Business. Most of that time has been in the molecular and biotechnology fields. His experience includes numerous positions in Sales and Marketing, establishing Direct Sales, Service and Support companies in Europe and Australia, and managing Distributor Sales in over 55 countries worldwide. He has directly managed employees in Japan, China and most major EU countries.
Mr. McMullin has worked in small, medium and large company settings, providing significantly increased Sales and Market Share in each case. He has routinely launched New Products into foreign countries, directed foreign country Product Registrations and led Special Project Teams in support of CE Marking, New Product Development, and New Business Development. He has initiated the licensing of Products to foreign companies, participated twice in corporate IPOs when going public and conducted numerous International Sales, Marketing and Service Meetings. Mr. McMullin is known for cultivating strong working relationships with people at all levels, both inside and outside of the company, and in working together in developing successful results. Mr. McMullin earned a Master’s Degree in International Management, graduating with honors from the American Graduate School of International Management (Thunderbird). He also holds a Bachelor’s Degree in Business Administration, graduating Magna Cum Laude, from Arizona State University.
JASON GERHOLD
JASON GERHOLD
GLOBAL DIRECTOR OF REGULATORY, QUALITY, AND CLINICAL AFFAIRS

Jason Gerhold joined Invivoscribe in 2012 and serves as the Global Director of Regulatory, Quality, and Clinical Affairs focusing on developing high quality diagnostics that meet both international pathology needs and support pharma partner’s drug development programs. He directly manages employees in the US, Japan, and China, and is responsible for worldwide compliance to relevant laws, regulations, and standards.
Mr. Gerhold has over 20 years of experience in the biotech industry with biologic therapeutics and diagnostics, including process development, regulatory, quality, and clinical roles. Mr. Gerhold has worked in small, medium and large companies; successfully registering IVD and CDx products in several international markets, developing, improving, and maintaining quality management systems while serving as the management representative to regulatory authorities, and leading clinical teams managing international registrational studies. He is known for building strong rapport with regulators and working well with research and pharma teams resulting in highly successful partnerships. He has completed trainings and/or accreditations for ISO 13485 Lead Auditor, Six Sigma Greenbelt, Clinical Trials Administration, Project Management, and CTD writing.
JORDAN THORNES
JORDAN THORNES
GLOBAL DIRECTOR OF CLINICAL LABS

Jordan Thornes joined Invivoscribe in 2004 and currently serves as the Global Director of Clinical Labs. In this role, he is responsible for leading Invivoscribe’s global network of clinical labs, The Laboratory for Personalized Molecular Medicine®, (LabPMM®).
There are currently four such LabPMM facilities which are strategically located globally in San Diego, USA; Hallbergmoos (Munich), Germany; Shanghai, China and Kawasaki (Tokyo), Japan.  LabPMM aids patients and pharmaceutical companies worldwide with globally standardized and clinically-actionable diagnostic methods. LabPMM utilizes proprietary biomarkers to select the correct patients and monitor and track their critically important response throughout the course of their disease.
ANDREIA DE ALBUQUERQUE, PH.D.
ANDREIA DE ALBUQUERQUE, PH.D.
DIRECTOR OF BUSINESS DEVELOPMENT

Dr. Andreia de Albuquerque joined Invivoscribe in 2015 and currently serves as the Director of Business Development. In this role, she is responsible for leading Invivoscribe’s global partnerships with Pharma and Biotech’s, focusing on companion diagnostics development, custom assay development, clinical trial testing, corporate partnerships and other strategic relationships.
Prior to joining Invivoscribe, Dr. de Albuquerque has held roles in precision molecular diagnostics, focusing on development, implementation and validation of PCR and NGS assays for diagnostic and research purposes. Her work has resulted in several peer-reviewed publications and participations in international conferences. During this time, she was also responsible for overseeing laboratory diagnostic teams and operations.
Her extensive expertise in precision diagnostics and understanding of assay development and clinical testing, paved the way into Business Development, where she focus on accelerating drug approvals, by building successful partnerships, providing technical expertise and working closely with biomarker leaders, sample operations, clinical science and regulatory to implement CDx, IVD and R&D assays in clinical trials.
Dr. de Albuquerque earned her degree in Biology from the University of Coimbra (Portugal) and a combined Ph.D. in Oncology and Molecular Biology from the University of Dresden (Germany).
YING HUANG, PH.D.
YING HUANG, PH.D.
SR. DIRECTOR OF PRODUCT DEVELOPMENT

Dr. Ying Huang joined Invivoscribe in 2010 and currently serves as the Sr. Director of Product Development. In this role, she is responsible for leading Invivoscribe’s product development activities to address unmet clinical needs in the fields of molecular diagnostic and precision medicine.
Dr. Huang has over 25 years of research and industry experience with a broad knowledge in technology and assay development. She is passionate about developing novel methods using cutting edge technologies to improve lives with precision diagnostics. She has successfully led development teams through entire product development life cycle, from feasibility to RUO, CLIA and IVD grade product launches and post market support under respective regulatory standards. Prior to Invivoscribe, Dr. Huang worked at Illumina, ACEA Biosciences, Nanogen and MD Anderson Cancer Center. In those roles, she developed a variety of techniques ranging from isolating CTC using microfluidic devices to detecting biowarfare agents using electronic microarray. Dr. Huang was the PI for research grants from DARPA and NIH. She is the co-author of more than 60 publications and meeting abstracts and is the co-inventor of 9 patents.
Dr. Huang received her Ph.D in Electrical Engineering from Bangor University, UK and B.E. in Electronic Engineering from Xidian University, China.
KASEY HUTT, PH.D.
KASEY HUTT, PH.D.
SR. MANAGER OF BIOINFORMATICS

Dr. Kasey Hutt joined Invivoscribe in 2014 and currently serves as the Sr. Manager of Bioinformatics. In this role, he is responsible for leading Invivoscribe’s bioinformatics development to provide crucial analysis solutions to streamline the path from NGS assay data to functional information.
Dr. Hutt has over 20 years of research and industry experience in bioinformatics, with over 20 publications covering fields in blood cancers, ALS, transcriptome networks and chromatin remodeling. Prior to joining Invivoscribe, Dr. Hutt worked as a postdoctoral student in Dr. Gene Yeo’s lab at UC San Diego, studying RNA-binding proteins on a transcriptome-wide scale. Within the context of the devastating disease Amyotrophic Lateral Sclerosis (ALS), he published multiple papers elucidating the RNA-processing connection between TDP-43 and ALS. Before receiving his Ph.D. in Bioinformatics from UC San Diego, Dr. Hutt was a graduate student in Dr. Michael G. Rosenfeld’s lab at UC San Diego, studying DNA-binding proteins and chromatin remodeling in the context of nuclear receptors on a genome-wide scale.

Dr. Hutt earned his Ph.D. in Bioinformatics from UC San Diego, and his B.S. in Biochemistry from the University of New Mexico.